-
FDA approves Moderna RSV vaccine for seniors
The FDA has approved Moderna’s RSV vaccine for older adults. Courtesy: Moderna The Food and Drug Administration on Friday approved Moderna’s vaccine for respiratory syncytial virus for adults ages 60 and above, the company’s second-ever product to enter the U.S. market. The decision is a win for Moderna, which desperately needs another revenue source amid…
-
Neuralink competitor Precision Neuroscience testing human mind implant
Dr. Joshua Bederson places Precision Neuroscience’s electrodes onto a brain. Ashley Capoot As the lights dimmed in an operating room at The Mount Sinai Hospital in New York City, Dr. Joshua Bederson prepared to make history. Bederson, system chair for the Department of Neurosurgery at Mount Sinai Health System, is no stranger to long hours…
-
Pfizer declares new value slicing program
Exterior view of the Pfizer headquarters building in New York City on Jan. 29, 2023. Kena Betancur | Corbis News | Getty Images Pfizer on Wednesday said it has launched a new multiyear program to reduce costs as it works to rebound from the rapid decline of its Covid business. The announcement is in addition…
-
FDA approves Amgen small cell lung most cancers remedy
The Amgen headquarters in Thousand Oaks, California. Eric Thayer | Bloomberg | Getty Images The Food and Drug Administration on Thursday approved Amgen‘s therapy for patients with the most deadly form of lung cancer. The agency cleared the drug, which will be marketed under the name Imdelltra, as a second or later line of treatment…
-
Issues that wealthy individuals face, in line with therapists
Depressed young male smoking cigarette, drinking alcohol and holding his head in hand. Mixmike | E+ | Getty Images Can money buy happiness? Contrary to what some may think, a million-dollar paycheck does not necessarily come with a problem free pass. While wealth can bring with it some unconventional problems — such as being denied…
-
Falling fertility charges pose main challenges for the worldwide financial system
Terry Vine | Getty Images Falling fertility rates are set to spark a transformational demographic shift over the next 25 years, with major implications for the global economy, according to a new study. By 2050, three-quarters of countries are forecast to fall below the population replacement birth rate of 2.1 babies per female, research published…
-
Ambient medical documentation steals the present
Attendees at HIMSS in Orlando, Florida 2024. Courtesy of HIMSS The hottest new technology for doctors promises to bring back an age-old health-care practice: face-to-face conversations with patients. As more than 30,000 health and tech professionals gathered among the palm trees at the HIMSS conference in Orlando, Florida, this week, ambient clinical documentation was the…
-
Eli Lilly faucets Amazon Pharmacy to assist ship Zepbound, different medication
Close-up of a hand holding a cellphone displaying the Amazon Pharmacy system, Lafayette, California, September 15, 2021. Smith Collection | Gado | Getty Images Eli Lilly on Wednesday said Amazon Pharmacy will help send certain prescription drugs, including the red-hot weight loss treatment Zepbound, to patients’ homes through the drugmaker’s new direct-to-consumer program. Starting Wednesday,…
-
Weight reduction tablet might change into a best-in-class drug
Novo Nordisk CEO Lars Fruergaard Jørgensen on Friday said the company’s experimental weight loss pill, amycretin, could eventually become a best-in-class treatment for obesity. The Danish drugmaker is racing to capitalize on the runaway success of its blockbuster weight loss drug Wegovy by developing a new generation of treatments for obesity, including more convenient and…
-
Viking Therapeutics emerges as competitor
Cr | Istock | Getty Images Biotech company Viking Therapeutics has emerged as a strong potential entrant — or takeover target — in the budding weight loss drug market. Viking is just one of several companies racing to join the growing space. Some analysts say the market could be worth $100 billion by the end…
